Trial of Terbutaline for the Treatment of Status Asthmaticus in Children

Completed · Phase 4

Conditions studied: Status Asthmaticus

In brief

Although widely used for the treatment of pediatric status asthmaticus, intravenous terbutaline has potentially significant side effects; may not improve outcomes; and may increase Intensive Care Unit (ICU) length of stay. This study is designed to test the efficacy of intravenous terbutaline for the treatment of status asthmaticus by adding intravenous terbutaline or placebo to standard asthma treatment. The dose of terbutaline or placebo will be titrated according to severity of illness as quantified by a validated clinical asthma score. Differences in outcomes between the study groups, such as length of stay, hospital costs, and lung function will be compared.

Key facts

Study ID

NCT00124995

Run by

Connecticut Children's Medical Center

People needed

40

Starts

2003-10-01

Expected to finish

2006-10-01

Last updated by the study team

2013-02-15

Who can join

Age: any, up to 18. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Admission to the Connecticut Children's Medical Center (CCMC) Pediatric Intensive Care Unit (PICU) with a primary admission diagnosis of status asthmaticus
• Modified Pulmonary Index Score (MPIS) of greater than or equal to 12
• Age between birth and 18 years old

You may not qualify if…

• Pre-existing cardiac or pulmonary disease
• Existing respiratory failure (requiring invasive or non-invasive mechanical ventilation)
• Hemodynamic or cardiovascular instability requiring inotropic support
• The patient meets one of the criteria for withdrawal from the study due to patient safety concerns

Where it is running

• CT Children's Medical Center — Hartford, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.